Cargando…

Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer

BACKGROUND: Bevacizumab improves progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer patients however currently there are no biomarkers that predict response to this treatment. The aim of this study was to assess if differential protein expression can differenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Petra, Noonan, Sinead, Mullen, Michael P, Scaife, Caitriona, Tosetto, Miriam, Nolan, Blathnaid, Wynne, Kieran, Hyland, John, Sheahan, Kieran, Elia, Giuliano, O’Donoghue, Diarmuid, Fennelly, David, O’Sullivan, Jacintha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289341/
https://www.ncbi.nlm.nih.gov/pubmed/25428203
http://dx.doi.org/10.1186/1471-2407-14-887
_version_ 1782352097568620544
author Martin, Petra
Noonan, Sinead
Mullen, Michael P
Scaife, Caitriona
Tosetto, Miriam
Nolan, Blathnaid
Wynne, Kieran
Hyland, John
Sheahan, Kieran
Elia, Giuliano
O’Donoghue, Diarmuid
Fennelly, David
O’Sullivan, Jacintha
author_facet Martin, Petra
Noonan, Sinead
Mullen, Michael P
Scaife, Caitriona
Tosetto, Miriam
Nolan, Blathnaid
Wynne, Kieran
Hyland, John
Sheahan, Kieran
Elia, Giuliano
O’Donoghue, Diarmuid
Fennelly, David
O’Sullivan, Jacintha
author_sort Martin, Petra
collection PubMed
description BACKGROUND: Bevacizumab improves progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer patients however currently there are no biomarkers that predict response to this treatment. The aim of this study was to assess if differential protein expression can differentiate patients who respond to chemotherapy and bevacizumab, and to assess if select proteins correlate with patient survival. METHODS: Pre-treatment serum from patients with metastatic colorectal cancer (mCRC) treated with chemotherapy and bevacizumab were divided into responders and nonresponders based on their progression free survival (PFS). Serum samples underwent immunoaffinity depletion and protein expression was analysed using two-dimensional difference gel electrophoresis (2D-DIGE), followed by LC-MS/MS for protein identification. Validation on selected proteins was performed on serum and tissue samples from a larger cohort of patients using ELISA and immunohistochemistry, respectively (n = 68 and n = 95, respectively). RESULTS: 68 proteins were identified following LC-MS/MS analysis to be differentially expressed between the groups. Three proteins (apolipoprotein E (APOE), angiotensinogen (AGT) and vitamin D binding protein (DBP)) were selected for validation studies. Increasing APOE expression in the stroma was associated with shorter progression free survival (PFS) (p = 0.0001) and overall survival (OS) (p = 0.01), DBP expression (stroma) was associated with shorter OS (p = 0.037). Increasing APOE expression in the epithelium was associated with a longer PFS and OS, and AGT epithelial expression was associated with a longer PFS (all p < .05). Increasing serum AGT concentration was associated with shorter OS (p = 0.009). CONCLUSIONS: APOE, DBP and AGT identified were associated with survival outcomes in mCRC patients treated with chemotherapy and bevacizumab. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2407-14-887) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4289341
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42893412015-01-11 Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer Martin, Petra Noonan, Sinead Mullen, Michael P Scaife, Caitriona Tosetto, Miriam Nolan, Blathnaid Wynne, Kieran Hyland, John Sheahan, Kieran Elia, Giuliano O’Donoghue, Diarmuid Fennelly, David O’Sullivan, Jacintha BMC Cancer Research Article BACKGROUND: Bevacizumab improves progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer patients however currently there are no biomarkers that predict response to this treatment. The aim of this study was to assess if differential protein expression can differentiate patients who respond to chemotherapy and bevacizumab, and to assess if select proteins correlate with patient survival. METHODS: Pre-treatment serum from patients with metastatic colorectal cancer (mCRC) treated with chemotherapy and bevacizumab were divided into responders and nonresponders based on their progression free survival (PFS). Serum samples underwent immunoaffinity depletion and protein expression was analysed using two-dimensional difference gel electrophoresis (2D-DIGE), followed by LC-MS/MS for protein identification. Validation on selected proteins was performed on serum and tissue samples from a larger cohort of patients using ELISA and immunohistochemistry, respectively (n = 68 and n = 95, respectively). RESULTS: 68 proteins were identified following LC-MS/MS analysis to be differentially expressed between the groups. Three proteins (apolipoprotein E (APOE), angiotensinogen (AGT) and vitamin D binding protein (DBP)) were selected for validation studies. Increasing APOE expression in the stroma was associated with shorter progression free survival (PFS) (p = 0.0001) and overall survival (OS) (p = 0.01), DBP expression (stroma) was associated with shorter OS (p = 0.037). Increasing APOE expression in the epithelium was associated with a longer PFS and OS, and AGT epithelial expression was associated with a longer PFS (all p < .05). Increasing serum AGT concentration was associated with shorter OS (p = 0.009). CONCLUSIONS: APOE, DBP and AGT identified were associated with survival outcomes in mCRC patients treated with chemotherapy and bevacizumab. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2407-14-887) contains supplementary material, which is available to authorized users. BioMed Central 2014-11-27 /pmc/articles/PMC4289341/ /pubmed/25428203 http://dx.doi.org/10.1186/1471-2407-14-887 Text en © Martin et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Martin, Petra
Noonan, Sinead
Mullen, Michael P
Scaife, Caitriona
Tosetto, Miriam
Nolan, Blathnaid
Wynne, Kieran
Hyland, John
Sheahan, Kieran
Elia, Giuliano
O’Donoghue, Diarmuid
Fennelly, David
O’Sullivan, Jacintha
Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer
title Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer
title_full Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer
title_fullStr Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer
title_full_unstemmed Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer
title_short Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer
title_sort predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289341/
https://www.ncbi.nlm.nih.gov/pubmed/25428203
http://dx.doi.org/10.1186/1471-2407-14-887
work_keys_str_mv AT martinpetra predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer
AT noonansinead predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer
AT mullenmichaelp predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer
AT scaifecaitriona predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer
AT tosettomiriam predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer
AT nolanblathnaid predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer
AT wynnekieran predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer
AT hylandjohn predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer
AT sheahankieran predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer
AT eliagiuliano predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer
AT odonoghuediarmuid predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer
AT fennellydavid predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer
AT osullivanjacintha predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer